8-K: Tempus AI Enters Agreements with AstraZeneca and Pathos AI for Oncology Model Development

Tempus AI collaborates with AstraZeneca and Pathos AI to develop a foundational large multimodal model in oncology, involving data licensing and financial transactions.

Summary

• Tempus AI has entered into agreements with AstraZeneca and Pathos AI to develop a foundational large multimodal model in the field of oncology.
• AstraZeneca will pay Tempus $35 million for the development of the Foundational Model.
• Tempus will license a comprehensive de-identified multi-modal dataset to Pathos for the development and training of the Foundational Model.
• Pathos will pay Tempus data license fees of $200 million over a three-year period, including an upfront payment of $50 million.
• Tempus will receive a license to use the Foundational Model upon its completion, with certain field restrictions and the right of sublicense to AstraZeneca.
• Tempus will pay Pathos $35 million in consideration of Pathos' commitments under the Pathos Master Agreement.
• Pathos may pay up to 50% of the data license fees owed to Tempus in shares of Pathos Series D Preferred Stock.

Sentiment

Score: 7

Explanation: The announcement is positive due to the new partnerships and revenue streams, but there are some costs and risks associated with the agreements.

Positives

• Tempus AI secures a $35 million payment from AstraZeneca for the development of the Foundational Model.
• Tempus AI will receive $200 million in data license fees from Pathos over three years, with an initial payment of $50 million.
• Tempus gains a license to use the Foundational Model, enhancing its capabilities in oncology.
• The collaboration with AstraZeneca and Pathos AI positions Tempus as a key player in the development of advanced AI models for oncology.

Negatives

• Tempus will pay Pathos $35 million in consideration of Pathos' commitments under the Pathos Master Agreement.
• Pathos has the option to pay up to 50% of the data license fees in shares of Pathos Series D Preferred Stock, which could impact the cash flow to Tempus.

Risks

• The success of the Foundational Model depends on the development, validation, and maintenance by Pathos.
• The value of Pathos Series D Preferred Stock, if received as payment, is subject to market fluctuations and Pathos' performance.
• The field restrictions on Tempus' license to use the Foundational Model could limit its application in certain areas.
• The reliance on de-identified datasets could raise concerns about data privacy and security.

Future Outlook

The agreements aim to develop a foundational large multimodal model in oncology, with potential for future applications and revenue streams for Tempus AI.

Industry Context

This announcement highlights the increasing trend of pharmaceutical companies partnering with AI and data analytics firms to accelerate drug discovery and development in oncology.

Comparison to Industry Standards

• Similar collaborations in the pharmaceutical industry include Roche's partnership with Flatiron Health to use real-world data in oncology research.
• Other companies like Foundation Medicine also provide comprehensive genomic profiling services for cancer patients, similar to Tempus' data offerings.
• The $200 million data license fee over three years is a significant investment, comparable to other large-scale data partnerships in the healthcare sector.

Stakeholder Impact

• Shareholders may react positively to the new partnerships and potential revenue streams.
• Employees may benefit from the company's growth and expansion into new areas.
• Customers may gain access to more advanced AI-driven solutions for oncology.

Next Steps

• Pathos will develop, validate, and maintain the Foundational Model.
• Tempus will license the de-identified multi-modal dataset to Pathos.
• Pathos will make payments to Tempus over the next three years.
• Tempus will receive a license to use the Foundational Model upon completion.

Key Dates

Keywords

oncology, multimodal model, data licensing, artificial intelligence, AstraZeneca, Pathos AI, Tempus AI